pharmaphorum7d
Regeneron's Inmazeb named Galien's Best Biotech Product
Dr George D. Yancopoulos, Regeneron’s chief scientific officer, said: “We are honoured that the Galien Foundation has recognised Inmazeb […] Our ability to rapidly respond to Ebola was based ...
Mena FN22d
Inmazeb Market Analysis: Key Trends, Share, Growth Drivers, And Forecast 2025-2034
Who Are the Key Players in the Inmazeb Market? .A leading company in the Inmazeb market is Regeneron Pharmaceuticals Inc. .The market remains highly competitive, with companies focusing on ...
Seeking Alpha3d
REGN Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals ... In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including ...
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...
Yahoo Finance3d
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for ...
Morningstar3d
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
About Regeneron and Sanofi’s COPD Clinical Research Program Regeneron and Sanofi are motivated to transform the treatment paradigm of COPD by examining the role different types of ...
Yahoo Finance24d
Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?
It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...
manilatimes3d
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Regeneron and Sanofi are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through the clinical assessment of ...
Yahoo Finance3d
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for ...
Insider Monkey13d
Jim Cramer Wants You to ‘Own’ Regeneron Pharmaceuticals (REGN) Shares
In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc (NASDAQ:REGN) stands against other stocks that Jim Cramer discusses. Jim Cramer in a recent program on CNBC ...
Seeking Alpha4d
Emergent BioSolutions: I See Further Downside Ahead In This Value Trap
Indeed, the rights remain held by Ridgeback, and Regeneron are also developing a treatment to rival this one. In any case, sales from these other treatments represented just $94 million (just over ...